All have been shown to promote EMT and tumor invasion, while macrophage-derived CCL22 (27, 28) drives alternative macrophage activation and IL-8 secretion (29) and recruits immunosuppressive cells to the tumor microenvironment (30). The gene discussed is CCL22; the disease is neoplasm.